Skip to main content
TipRanks
Go Ultimate75% OFF

NeuroOne Medical Technologies (NMTC) Q3 2026 Earnings Report

203 Followers

NMTC Q3 2026 EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.23
Beat/Miss
Met expectations
One Year Ago EPS
-$0.18

NMTC Q3 2026 Revenue Results

Actual Revenue
$1.97M
Expected Revenue
$1.97M
Beat/Miss
Beat by +$1,105
YoY Revenue Growth
+16.34%

Earnings Announcement Details

Quarter
Q3 2026
Date
08/19/2026
Time
TBA
Conference Call
Wednesday, August 19, 2026
NMTC Upcoming Earnings

NeuroOne Medical Technologies's next earnings date is estimated for December 16, 2026, based on past reporting schedules.

Q3 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Aug 19, 2026|% Change Since:-60.37%|
Earnings Call Sentiment|Neutral

The call delivered strong operational and clinical progress — including double-digit revenue growth (+16% YoY), 43% growth in orders, improved gross margins (+6.0 percentage points), ISO 13485 certification, and meaningful advances across product lines (OneRF, Trigeminal, StereoCED, BVNA). However, these positives are balanced by material near-term challenges: manufacturing lead times and backlog that constrain revenue recognition, rising operating expenses and widening net loss, and a significant decline in cash and working capital that creates liquidity pressure. Management has mitigation plans (second manufacturing site, ATM raises, supply acceleration) and clear clinical/regulatory milestones, but the financial and execution risks temper the upside from operational wins.

Company Guidance

Guidance for fiscal 2026 reiterated expected aggregate product orders of approximately $11.2 million and recognized revenue of $9.2–$10.5 million (timing-dependent); Q3 product revenue was $2.0M (up 16% YoY from $1.7M) with $2.7M of orders in the quarter (up 43% YoY) and a $1.7M backlog as of June 30, 2026 that management expects to address by the end of calendar Q4 2026 through supplier acceleration and qualification of a second, larger manufacturing site expected in early 2027. Gross margin expanded to 59.9% (product gross profit $1.2M vs 53.9% a year ago), total operating expenses were $3.6M (R&D $1.4M; SG&A $2.2M), net loss was $2.0M ($0.23 basic / $0.28 diluted) versus $1.5M ($0.19 / $0.22) prior-year, cash and cash equivalents were $2.0M (vs $6.6M on 9/30/25) with $1.1M AR expected to convert in Q4, working capital $3.7M (vs $7.9M), no debt, and $1.4M raised via ATM in 2026 ($0.4M in Q3; $1.0M on July 13 via 400,346 shares); strategic milestones/timing include ISO 13485 certification enabling international expansion, StereoCED aimed for investigational human studies by end-September 2026, and a BVNA 510(k) submission targeted in H2 2027, while a lead investor increased ownership from 7.4% to 12.5%.

  • Product Revenue GrowthProduct revenue for OneRF grew 16% year-over-year to $2.0M in Q3 FY2026 (from $1.7M in Q3 FY2025).
  • Orders and Backlog DemandQuarterly product orders totaled $2.7M, representing 43% year-over-year growth; company reported aggregate product orders of approximately $11.2M for FY2026 (recognition timing expected to result in $9.2M–$10.5M recognized revenue).
  • Improved Gross MarginProduct gross margin expanded to 59.9% in Q3 FY2026 from 53.9% a year earlier (+6.0 percentage points), driven by a more favorable product mix.
  • ISO 13485 Certification AchievedReceived ISO 13485 certification, enabling international market access for OneRF Brain Ablation, OneRF Trigeminal Neuralgia Ablation and Evo Cortical and sEEG diagnostic product lines — a key regulatory/quality milestone reached earlier than projected.
  • Clinical and Publication MilestonesJournal of Neurosurgery published a Mayo Clinic retrospective study supporting OneRF use in patients with implanted neuromodulation devices (showing meaningful seizure reduction and no hardware interference), expanding the treatable patient pool.
  • Commercial and Marketing Wins for Trigeminal SystemOneRF Trigeminal Nerve Ablation System featured in media (patient reported being pain-free); U.S. disposables market (ex-hardware) estimated at $40M concentrated in ~30 centers, with expected short learning curve and distributor expansion plans.
  • StereoCED Program ProgressRobotic-assisted StereoCED drug-delivery platform targeting investigational human studies by end of September; preclinical collaborations with University of Minnesota and Mayo Clinic, animal studies starting this month with data expected this fall, and first device sales to pharma for nonhuman primate studies anticipated later this year.
  • BVNA Development ProgressCompleted user design requirements and initiated preclinical testing for Basivertebral Nerve Ablation System; regulatory path assessed as likely 510(k) with target submission in H2 2027, leveraging existing OneRF generator and accessories.
  • Investor and Balance Sheet Support ActionsLead investor increased holdings from 7.4% to 12.5%; company raised $0.4M during the quarter and a subsequent $1.0M via ATM; no debt outstanding as of June 30, 2026.

NMTC Earnings History

NMTC earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Dec 16, 20262026 (Q4)-0.19--0.3――
Aug 19, 20262026 (Q3)-0.23-0.23-0.18-27.78% (-0.05)
May 12, 20262026 (Q2)-0.23-0.25-0.4240.48% (+0.17)
Feb 17, 20262026 (Q1)-0.24-0.170.36-147.22% (-0.53)
Dec 17, 20252025 (Q4)-0.24-0.30-0.6654.55% (+0.36)
Aug 14, 20252025 (Q3)-0.30-0.18-0.670.00% (+0.42)
May 13, 20252025 (Q2)-0.54-0.42-0.6636.36% (+0.24)
Feb 12, 20252025 (Q1)―0.36-0.84142.86% (+1.20)
Dec 17, 20242024 (Q4)―-0.66-1.0335.67% (+0.37)
Aug 14, 20242024 (Q3)-0.54-0.60-1.250.00% (+0.60)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed